Barclays lowered the firm’s price target on Pfizer to $35 from $38 and keeps an Equal Weight rating on the shares. The analyst says U.S. Biopharma enters the Q3 earnings season “with still widely negative sentiment.” The firm is “positively-biased” into the Q3 setups against a backdrop of solid script trends, poor sentiment, and “idiosyncratic” headwinds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- Developers of mRNA Vaccines Honored with Nobel Prize
- Unusually active option classes on open September 29th
- Structure Therapeutics’ GBSR-1290 data ‘firmly positive’, says BMO Capital
- Pfizer, BioNTech announce Canada authorization of monovalent vaccine
- Ginkgo Bioworks announces multi-target RNA discovery collaboration with Pfizer